Increased Selectivity toward Cytoplasmic versus Mitochondrial Ribosome Confers Improved Efficiency of Synthetic Aminoglycosides in Fixing Damaged Genes: A Strategy for Treatment of Genetic Diseases Caused by Nonsense Mutations-Reference-Cited by-同舟云学术

Increased Selectivity toward Cytoplasmic versus Mitochondrial Ribosome Confers Improved Efficiency of Synthetic Aminoglycosides in Fixing Damaged Genes: A Strategy for Treatment of Genetic Diseases Caused by Nonsense Mutations

Published:2012-11-29 Issue:23 Volume:55 Page:10630-10643
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Kandasamy Jeyakumar¹,Atia-Glikin Dana¹,Shulman Eli¹,Shapira Katya¹,Shavit Michal¹,Belakhov Valery¹,Baasov Timor¹

Affiliation:

1. The Edith and Joseph Fischer Enzyme Inhibitors Laboratory, Schulich Faculty of Chemistry, Technion - Israel Institute of Technology, Haifa 32000, Israel

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm3012992

Reference40 articles.

1. Suppression of nonsense mutations as a therapeutic approach to treat genetic diseases

2. A meta-analysis of nonsense mutations causing human genetic disease

3. Suppression of a nonsense mutation in mammalian cellsin vivoby the aminoglycoside anthiotics G–418 and paromomycin

4. Aminoglycoside-induced Translational Read-through in Disease: Overcoming Nonsense Mutations by Pharmacogenetic Therapy

5. When running a stop sign may be a good thing

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic targeting of TP53 nonsense mutations in cancer;Upsala Journal of Medical Sciences;2024-05-27

2. Genetics of cystogenesis in base-edited human organoids reveal therapeutic strategies for polycystic kidney disease;Cell Stem Cell;2024-04

3. Readthrough Activators and Nonsense-Mediated mRNA Decay Inhibitor Molecules: Real Potential in Many Genetic Diseases Harboring Premature Termination Codons;Pharmaceuticals;2024-02-28

4. Small molecule modulators of cystic fibrosis transmembrane conductance regulator (CFTR): Structure, classification, and mechanisms;European Journal of Medicinal Chemistry;2024-02

5. Cystic Fibrosis Modulator Therapies: Bridging Insights from CF to other Membrane Protein Misfolding Diseases;Israel Journal of Chemistry;2024-01-24